Viewing data from:

MINOCIN

NDA

MINOCYCLINE HYDROCHLORIDE | N050315 | TRIAX PHARMACEUTICALS LLC

2 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

3 cases on OB patents (1 active) from PACER

Case	Court	Filed	Status	Judge
Melinta Subsidiary Corp. et al v. Gland Pharma Limited 1:2025cv03676 4 patentsANDA 220209minocycline hydrochloride	N.D. Ill.	2025-04-04	Active	—
Melinta Therapeutics, LLC et al v. Nexus Pharmaceuticals, Inc. 1:2021cv05995 minocycline hydrochloride	N.D. Ill.	2021-11-09	Terminated 2024-11-15	—
MELINTA THERAPEUTICS, LLC et al v. NEXUS PHARMACEUTICALS, INC. 2:2021cv11198 minocycline hydrochloride	D.N.J.	2021-05-13	Terminated 2021-11-05	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Citizen Petitions

1 petition from Regulations.gov

Petition	Type	Filed	Status	Petitioner
Citizen Petition from Pitney, Hardin, Kipp Szuch FDA-1998-P-0835 · 4 docket documents Law firm Pitney, Hardin, Kipp & Szuch filed this petition on March 31, 1998, pursuant to section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting permission to file an Abbreviated Antibiotic Drug Application for Minocycline Hydrochloride Tablets in a 75 mg dosage strength, which d	Other	2019-09-04	Granted	Pitney, Hardin, Kipp Szuch

Source: Regulations.gov. FDA citizen petitions matched by application number.

Clinical Trials

188 trials from ClinicalTrials.gov — 2 recruiting, 1 active, 126 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Regeneration of Immature Teeth. Case Series NCT03507556	N/A	Active	Jordan University of Science and Technology	40	2010-06-28 → 2030-12-01
Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery NCT01422148	Phase 2	Not Yet Recruiting	Baystate Medical Center	60	2025-07 → 2028-01-24
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response NCT03414502	Phase 3	Recruiting	University of Nebraska	400	2007-12-10 → 2029-03
Minocycline as Adjunctive Treatment for Treatment Resistant Depression NCT03947827	Phase 3	Completed	Centre for Addiction and Mental Health	76	2020-02-01 → 2025-01-07
Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis NCT00529555	Phase 3	Completed	Sunstar Americas	602	2006-01 → 2008-12
Minocycline and Perfusion Pressure Augmentation in Acute Spinal Cord Injury NCT00559494	Phase 1/2	Completed	University of Calgary	52	2004-06 → 2010-08
A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections NCT01049438	N/A	Completed	Natividad Medical Center	31	2006-08 → 2009-09
Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial NCT02263872	Phase 4	Completed	Pakistan Institute of Living and Learning	41	2014-10 → 2016-08
National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial NCT00063193	Phase 2	Completed	University of Rochester	195	2003-05 → 2005-07
A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.NCT04104685	Phase 2	Completed	Vyne Therapeutics Inc.	446	2019-09-18 → 2020-03-03

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Medicare Part D Spending

CMS annual spending data for Minocin (2024)

Total Spending

$767K

Total Claims

206

Beneficiaries

Avg Cost/Unit

$30.54

Spending Trend

$177K(2019)→$169K(2020)→$312K(2021)→$364K(2022)→$432K(2023)→$767K(2024)

YoY Change:+257.0%

5yr CAGR:-1.2%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain9 active DMFs7 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

HOVIONE FARMACIENCIA SAMINOCYCLINE HYDROCHLORIDE

DMF 137381998

CIPAN - COMPANHIA INDUSTRIAL PRODUTORA DE ANTIBIOTICOS SAMINOCYCLINE HYDROCHLORIDE

DMF 137581998

CURIA ITALY SRLMINOCYCLINE HYDROCHLORIDE (DIHYDRATE)

DMF 148022000

IDT AUSTRALIA LTDMINOCYCLINE HYDROCHLORIDE USP

DMF 150142000

ZHEJIANG HISUN PHARMACEUTICAL CO LTDMINOCYCLINE HYDROCHLORIDE USP

DMF 260502012

HOVIONE FARMACIENCIA SAMINOCYCLINE HYDROCHLORIDE MICRONIZED

DMF 290032015

ZHEJIANG MEDICINE CO LTDMINOCYCLINE HYDROCHLORIDE

DMF 326642018

CURIA ITALY SRLMINOCYCLINE HYDROCHLORIDE (DIHYDRATE) MICRONIZED

DMF 332792018

ZHEJIANG CHANGHAI PHARMACEUTICALS CO LTDMINOCYCLINE HYDROCHLORIDE USP

DMF 359392022

PARKE DAVIS AND COInactiveMINOCYCLINE HYDROCHLORIDE CAP

DMF 24081975

FINE CHEMICALS CORPInactiveMINOCYCLINE HYDROCHLORIDE

DMF 71991987

LEDERLE LABORATORIESInactiveMINOCYCLINE HYDROCHLORIDE

DMF 134041998

NIPPON KAYAKU CO LTDInactiveMINOCYCLINE HYDROCHLORIDE

DMF 137481998

KYOWA HAKKO KOGYO CO LTDInactiveMINOCYCLINE HYDROCHLORIDE

DMF 137551998

UNION QUIMICO FARMACEUTICA SA (UQUIFA SA)InactiveMINOCYCLINE HYDROCHLORIDE USP

DMF 151712000

HOVIONE FARMACIENCIA SAInactiveMINOCYCLINE

DMF 342172019

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 100MG BASE

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.

#002 — EQ 50MG BASE

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Approved Prior to Jan 1, 1982